170 results on '"Eggemann H"'
Search Results
2. Puerperal mastitis in the past decade: results of a single institution analysis
3. Laparoscopic-assisted vaginal hysterectomy versus vaginal hysterectomy for benign uterine diseases: a prospective, randomized, multicenter, double-blind trial (LAVA)
4. Breast cancer therapy in women under 35 years and between 50 and 69 years: influence of the observation period
5. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
6. Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer
7. Tumor characteristics and therapy of elderly patients with breast cancer
8. BRCA1 promoter methylation is a marker of better response to platinum–taxane-based therapy in sporadic epithelial ovarian cancer
9. Management der Axilla beim primär operablen Mammakarzinom
10. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)†
11. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
12. Impact of the Oncotype DX® Recurrence Score® Assay on therapy recommendations for ER-positive (ER+), node negative (N0) and node positive (N+) early breast cancer - Results of an interim analysis of the German decision impact study: V444
13. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial
14. Adjuvant treatment of breast cancer patients with 1–3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study
15. Abstract P1-13-01: Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosphamide and paclitaxel with a dose dense regimen with epirubicin and paclitaxel
16. Management of elderly women with endometrial cancer
17. Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival.
18. Comparison of survival of patients with endometrial cancer treated with systematic lymphadenectomy versus sentinel lymph node biopsy alone
19. Management of small T1a/b breast cancer by tumor subtype
20. Das Chorionkarzinom nach einer Terminschwangerschaft
21. Fallvorstellung Appendizitis in der Schwangerschaft
22. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)†
23. Vergleich der älteren metastasierten Mammakarzinompatientin mit der jüngeren hinsichtlich Tumorcharakteristika und Therapie
24. Überlebensvorteil einer Lymphonodektomie bei Endometriumkarzinom
25. 1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44)
26. Platelet Count After Chemotherapy is a Predictor for Outcome for Ovarian Cancer Patients
27. Accuracy of ultrasound-guided breast-conserving surgery in the determination of adequate surgical margins
28. Laparoskopisch assistierte vaginale Hysterektomie versus vaginale Hysterektomie – eine prospektive, randomisierte, Doppel-blind-Studie bei Patientinnen mit der Indikation zur vaginalen Hysterektomie
29. Ultrasound-guided breast-conserving surgery is superior to the palpation-guided surgery for palpable breast cancer
30. Endokrine Therapie des metastasierten Mammakarzinoms des Mannes – eine retrospektive Analyse von 80 Patienten im Vergleich mit 541 Frauen
31. Vergleich der älteren Mammakarzinompatientin mit der jüngeren hinsichtlich adjuvanter Therapie
32. Intraoperative Sonografie in der Behandlung des Mammakarzinoms
33. Intraoperative Ultrasound in the Treatment of Breast Cancer
34. Abstract OT2-2-05: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/− GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (GBG-54 MALE)
35. P2-12-26: Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer – Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease.
36. Postmastectomy radiotherapy in male breast cancer –20 Years follow-up data
37. Einfluss des Oncotype DX Recurrence Score auf Therapieempfehlungen beim ER-positiven (ER+), nodalnegativen (N0) und nodalpositiven (N+) frühen Mammakarzinom – Ergebnisse einer Interimsanalyse der Deutschen Decision-Impact-Studie
38. MR gestützte Freihandbiopsie kleiner suspekter Mammaläsionen mittels eines offenen 1 Tesla Tomographen
39. P206 German multicentre decision impact study of Oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER+) node negative (N0) and node positive (N+) early breast cancer
40. Comparative Study of Surgical Margins and Cosmetic Outcome in Lumpectomy versus Segmental Resection in Breast Cancer
41. Abstract S4-6: Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44)
42. Die B-Plastik – Eine retrospektive Studie zur Wertigkeit und Patientenzufriedenheit einer brusterhaltenden Therapie bei zentralem Sitz des Mammakarzinoms
43. Mammareduktionsplastik als Bestandteil der operativen Therapie des Mammakarzinoms – Welche Techniken sollten beherrscht werden?
44. Therapeutic management of male breast cancer in Germany.
45. Der Mammainfarkt als Differenzialdiagnose eines Tumors der laktierenden Mamma
46. Brustentzündungen
47. Wertigkeit der Segmentresketion (mit kaudalem und kranialen Schwenklappen) bei Patientinnen mit einem Mammakarzinom
48. Significant Changes in Circulating Plasma Levels of IGF1 and IGFBP3 after Conventional or Dose-Intensified Adjuvant Treatment of Breast Cancer Patients with one to three Positive Lymph Nodes
49. Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer
50. Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.